Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Validation of Townes As Mice As a Model of Chronic Kidney Disease and Venous Thrombosis Associated with Sickle Cell Trait

Malgorzata Kasztan, Steven P Grover, Fatima Trebak, Mohammad O Sako, Nigel S. Key, Rafal Pawlinski

Blood (2023) 142 (Supplement 1): 564.

https://doi.org/10.1182/blood-2023-186635

Published: 2023

Journal Articles

Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies

Jacqueline Poston, Siobhan Brown, Amy S Ginsburg, Anton Ilich, Heather Herren, Nahed El Kassar, Christopher Edward Jensen, Darrell J Triulzi, Nigel S. Key, Susanne May, Terry B Gernsheimer

Blood (2023) 142 (Supplement 1): 2667.

https://doi.org/10.1182/blood-2023-186654

Published: 2023

Journal Articles

Pharmacologic Reduction of Platelet Count Attenuates Whole Blood Hypofibrinolysis in a Mouse Model of Sickle Cell Disease

Anton Ilich, Karnsasin Seanoon, Fatima Trebak, Andras Gruber, Nigel S. Key, Rafal Pawlinski

Blood (2023) 142 (Supplement 1): 562.

https://doi.org/10.1182/blood-2023-187098

Published: 2023

Journal Articles

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

Blood (2023) 142 (Supplement 1): 1055.

https://doi.org/10.1182/blood-2023-187624

Published: 2023

Journal Articles

Hypertonicity and/or Acidosis Induce Marked Rheological Changes Under Hypoxic Conditions in Sickle Trait Red Blood Cells

Patrick Ellsworth, Izabela Pawlinski, Rachel Sielaty, Anton Ilich, Chatphatai Moonla, Yuriy Prokopenko, Dougald M. Monroe, Rafal Pawlinski, Nigel S. Key

Blood (2023) 142 (Supplement 1): 1113.

https://doi.org/10.1182/blood-2023-187112

Published: 2023

Journal Articles

Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease

Blood (2023) 141 (15): 1871–1883.

https://doi.org/10.1182/blood.2022017074

Published: 2023

Includes: Multimedia, Supplemental data

Journal Articles

Establishment and Utilization of an Advanced Practice Provider-Led Clinic for Newly Diagnosed Venous Thromboembolism

Cassiopeia Frank, Nigel S. Key, Micah J. Mooberry, Raj S. Kasthuri, Stephan Moll

Blood (2022) 140 (Supplement 1): 7887–7888.

https://doi.org/10.1182/blood-2022-170183

Published: 2022

Journal Articles

Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061)

Wolfgang A. Miesbach, Michael Recht, Nigel S. Key, Krupa Sivamurthy, Paul E. Monahan, Steven W. Pipe

Blood (2022) 140 (Supplement 1): 4913–4914.

https://doi.org/10.1182/blood-2022-166810

Published: 2022

Journal Articles

Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, Michiel Coppens, David Cooper, Robert Gut, Sergio Slawka, Stephanie Verweij, Ricardo Dolmetsch, Yanyan Li, Paul E. Monahan, Wolfgang A. Miesbach

Blood (2022) 140 (Supplement 1): 4910–4912.

https://doi.org/10.1182/blood-2022-166135

Published: 2022

Journal Articles

Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, David Cooper, Stephanie Verweij, Ricardo Dolmetsch, Jacqueline Tarrant, Yanyan Li, Paul E. Monahan, Wolfgang A. Miesbach

Blood (2022) 140 (Supplement 1): 4904–4906.

https://doi.org/10.1182/blood-2022-166745

Published: 2022

Journal Articles

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial

Terry B. Gernsheimer, Siobhan P. Brown, Darrell J. Triulzi, Nigel S. Key, Nahed El Kassar, Heather Herren, Jacqueline N. Poston, Michael Boyiadzis, Brandi N. Reeves, Subodh Selukar, Monica B. Pagano, Scott Emerson, Susanne May

Blood (2022) 140 (11): 1254–1262.

https://doi.org/10.1182/blood.2022016308

Published: 2022

Includes: Supplemental data

Journal Articles

Emizicumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner

Patrick Ellsworth, Dougald Monroe, Maureane Hoffman, Nigel S Key

Blood (2021) 138 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2021-148556

Published: 2021

Journal Articles

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Blood (2021) 138 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2021-144508

Published: 2021

Journal Articles

Inhibition of Factor XII Attenuates Prothrombotic Complications in Sickle Cell Mice

Erica Sparkenbaugh, Christina M Abrams, Megan D Miller, Brian C Cooley, Anton Ilich, Shreya Yadav, Michael Wallisch, Nigel S Key, Andras Gruber, Felicity N. E. Gavins, Rafal Pawlinski

Blood (2021) 138 (Supplement 1): 189.

https://doi.org/10.1182/blood-2021-152753

Published: 2021

Journal Articles

Cleavage of High Molecular Weight Kininogen and Bradykinin Release By Red Blood Cell Microvesicles As a Putative Mechanism for Hypotensive Transfusion Reactions

Michael W Henderson, Matthew Karafin, Anton Ilich, Nigel S Key

Blood (2021) 138 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2021-152595

Published: 2021

Journal Articles

Absence of Hyperactivation of Fibrinolysis Explains the Lack of Hemostatic Efficacy of Prophylactic Tranexamic Acid (TXA) in Hypoproliferative Thrombocytopenia

Anton Ilich, Terry B. Gernsheimer, Darrell J Triulzi, Heather Herren, Siobhan P Brown, Lori A Holle, Andrew T Lucas, Nahed El Kassar, Alisa S. Wolberg, Susanne May, Nigel S Key

Blood (2021) 138 (Supplement 1): 2094.

https://doi.org/10.1182/blood-2021-146898

Published: 2021

Journal Articles

Rituximab Monotherapy Is Effective for Inhibitor Eradication with Concomitant Porcine Factor VIII Followed By Emicizumab for Bleed Control in Acquired Hemophilia a

Patrick Ellsworth, Sheh-Li Chen, Christopher Wang, Nigel S Key, Alice Ma

Blood (2021) 138 (Supplement 1): 348.

https://doi.org/10.1182/blood-2021-154207

Published: 2021

Journal Articles

Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure

Michael W. Henderson, Erica M. Sparkenbaugh, Shaobin Wang, Anton Ilich, Denis F. Noubouossie, Reiner Mailer, Thomas Renné, Matthew J. Flick, James P. Luyendyk, Zu-Lin Chen, Sidney Strickland, R. Todd Stravitz, Keith R. McCrae, Nigel S. Key, Rafal Pawlinski

Blood (2021) 138 (3): 259–272.

https://doi.org/10.1182/blood.2020006198

Published: 2021

Includes: Supplemental data

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Utility of Inferior Vena Cava Filter in the Management of Venous Thromboembolism Among Patients with Brain Metastases: A Population-Based Study

Vaibhav Kumar, MBBS,MS, Ann M Brunson, MS, Anjlee Mahajan, MD, Nigel S. Key, MD, Ted Wun, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-138790

Published: 2020

NARROW

Validation of Townes As Mice As a Model of Chronic Kidney Disease and Venous Thrombosis Associated with Sickle Cell Trait

Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies

Pharmacologic Reduction of Platelet Count Attenuates Whole Blood Hypofibrinolysis in a Mouse Model of Sickle Cell Disease

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

Hypertonicity and/or Acidosis Induce Marked Rheological Changes Under Hypoxic Conditions in Sickle Trait Red Blood Cells

Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease

Establishment and Utilization of an Advanced Practice Provider-Led Clinic for Newly Diagnosed Venous Thromboembolism

Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial

Emizicumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Inhibition of Factor XII Attenuates Prothrombotic Complications in Sickle Cell Mice

Cleavage of High Molecular Weight Kininogen and Bradykinin Release By Red Blood Cell Microvesicles As a Putative Mechanism for Hypotensive Transfusion Reactions

Absence of Hyperactivation of Fibrinolysis Explains the Lack of Hemostatic Efficacy of Prophylactic Tranexamic Acid (TXA) in Hypoproliferative Thrombocytopenia

Rituximab Monotherapy Is Effective for Inhibitor Eradication with Concomitant Porcine Factor VIII Followed By Emicizumab for Bleed Control in Acquired Hemophilia a

Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Utility of Inferior Vena Cava Filter in the Management of Venous Thromboembolism Among Patients with Brain Metastases: A Population-Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only